Quarterly Consolidated Statement Of Cash Flows

Immuno-Biological Laboratories Co., Ltd. - Filing #7244299

Concept As at
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
190,290,000 JPY
144,191,000 JPY
Interest and dividends received
2,770,000 JPY
2,818,000 JPY
Interest paid
-3,658,000 JPY
-3,931,000 JPY
Income taxes paid
-5,906,000 JPY
-9,302,000 JPY
Net cash provided by (used in) operating activities
183,495,000 JPY
133,775,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-59,660,000 JPY
-16,160,000 JPY
Other, net
0 JPY
164,000 JPY
Net cash provided by (used in) investing activities
-53,660,000 JPY
-24,496,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
20,000,000 JPY
10,000,000 JPY
Repayments of long-term borrowings
-52,003,000 JPY
-14,008,000 JPY
Other, net
JPY
0 JPY
Net cash provided by (used in) financing activities
-31,755,000 JPY
991,000 JPY
Effect of exchange rate change on cash and cash equivalents
-2,486,000 JPY
2,700,000 JPY
Net increase (decrease) in cash and cash equivalents
95,593,000 JPY
112,971,000 JPY
Cash and cash equivalents
770,563,000 JPY
674,969,000 JPY
561,997,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.